{
    "clinical_study": {
        "@rank": "115966", 
        "arm_group": [
            {
                "arm_group_label": "IDegAsp 30 + placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin aspart + insulin degludec - low concentration 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp 40 + placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin aspart + insulin degludec - high concentration 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp 45 + placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin aspart + insulin degludec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp 55 + placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin aspart + insulin degludec - high concentration", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BIAsp 30 + placebo", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to compare insulin degludec and\n      insulin aspart (IDegAsp) co-formulations with separately injected, simultaneous doses of\n      insulin degludec (insulin 454) and insulin aspart, compared with biphasic insulin aspart 30\n      (NovoMix\u00ae 30) in subjects with type 1 diabetes mellitus. Each subject will be randomised to\n      four out of nine possible treatment arms. IDegAsp 40, IDegAsp 45, IDegAsp 55 and IDeg high\n      concentration were explorative formulations, not similar to the proposed commercial\n      formulation."
        }, 
        "brief_title": "Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Glycosylated haemoglobin A1c (HbA1c) below or equal to 10.0 % based on central\n             laboratory results\n\n          -  Diagnosed with type 1 diabetes and treated with insulin for above or equal to 12\n             months\n\n          -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  A subject with a history of significant multiple drug allergies or with a known or\n             suspected allergy to the trial product or any medicine chemically related to the\n             trialproduct, as judged by the Investigator\n\n          -  A subject who is known to have hepatitis or who is carrier of the Hepatitis B surface\n             antibodies, or has a positive result to the test for HIV antigen (HBsAg) or Hepatitis\n             C antibodies\n\n          -  A subject who has participated in any other trials involving investigational products\n             within the 3 months preceding the start of dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868568", 
            "org_study_id": "NN5401-1959", 
            "secondary_id": "2007-006110-42"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Insulin aspart + insulin degludec - low concentration 1", 
                    "Insulin aspart + insulin degludec - high concentration 1", 
                    "Insulin aspart + insulin degludec", 
                    "Insulin aspart + insulin degludec - high concentration"
                ], 
                "description": "Administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 30 + placebo", 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin degludec/insulin aspart 30", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 40 + placebo", 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin degludec/insulin aspart 40", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 45 + placebo", 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin degludec/insulin aspart 45", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 55 + placebo", 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin degludec/insulin aspart 55", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Insulin aspart + insulin degludec - low concentration 1", 
                    "Insulin aspart + insulin degludec - high concentration 1", 
                    "Insulin aspart + insulin degludec", 
                    "Insulin aspart + insulin degludec - high concentration"
                ], 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BIAsp 30 + placebo", 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "biphasic insulin aspart 30", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IDegAsp 30 + placebo", 
                    "IDegAsp 40 + placebo", 
                    "IDegAsp 45 + placebo", 
                    "IDegAsp 55 + placebo", 
                    "BIAsp 30 + placebo"
                ], 
                "description": "A single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "9", 
        "official_title": "A Randomised, Double-blind, Multiple Period Cross-over Trial Comparing Insulin 454 and Insulin Aspart Fixed Combination Products With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared to Biphasic Insulin Aspart 30 (NovoMix\u00ae 30) in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the insulin aspart concentration curve", 
            "safety_issue": "No", 
            "time_frame": "0-2 hours after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868568"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the glucose infusion rate curve", 
                "safety_issue": "No", 
                "time_frame": "0-26 hours after dosing"
            }, 
            {
                "measure": "Area under the serum insulin 454 concentration curve", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours after dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}